ABSTRACT
INTRODUCTION
Affective disorders, such as major depression, represent a serious health problem with long-lasting consequences for both patients and society (Greden, 2001 ).
Antidepressants, firstly discovered by serendipity, revolutionized the treatment of mood disorders (Nestler et al., 2002b ). Yet, more than half a century later, the treatment of these disorders remains a challenge. Only about 50% of depressed patients treated with currently available medications achieve complete remission (Nestler et al., 2002a; Fagiolini and Kupfer, 2003) . Moreover, rather poor tolerability of antidepressant drugs and late onset of their therapeutic effects further increase the risk of unsuccessful treatment (Berton and Nestler, 2006) . Altogether, this urges the introduction of newer medications with fundamentally different mechanisms of action than the older agents.
Agomelatine is a novel antidepressant which acts as a potent melatonergic (MT1 and MT2) receptor agonist (Audinot et al., 2003) and serotonergic (5-HT2C) receptor antagonist (Millan et al., 2003) . Current literature indicates that the therapeutic actions of agomelatine are mediated at least partly through different mechanisms than selective serotonin reuptake inhibitors (SSRI) or tricyclics (Hanoun et al., 2004) . For example, some of its effects may involve modulation of circadian rhythms and changes in sleep-wake cycle (Tuma et al., 2005; Kasper and Hamon, 2009 ). The antidepressant properties of agomelatine have been demonstrated both in animal models (Papp et al., 2003; Bourin et al., 2004; Barden et al., 2005; Bertaina-Anglade et al., 2006) and in clinical studies (Loo et al., 2002; Kennedy and Emsley, 2006; Pandi-Perumal et al., 2006a; Olie and Kasper, 2007; Goodwin et al., 2009 ). Yet, the effects of agomelatine merit further investigation.
Beneficial effects of antidepressant drugs are observed in depressed patients but not in healthy volunteers, suggesting that the neurochemical effects of antidepressants might differ in disturbed versus intact systems (Berton and Nestler, 2006) . Therefore, it is important to unravel agomelatine-mediated changes in the brain affected by psychopathology (clinical studies) or exposed to conditions that might predispose to mood disorders (animal models). It therefore seems a suitable approach to apply agomelatine treatment in chronically stressed animals, in order to reliably explore its beneficial actions and mechanisms behind them.
Stress, especially when severe and prolonged, is one of the major predisposing risk factors for developing depression (Kendler et al., 1999; Paykel, 2001 ). Animal models of chronic stress provide a valuable tool to investigate behavioral, endocrine and neurobiological changes underlying stress-related psychopathologies and 66 mechanism of antidepressant therapies (Fuchs et al., 2001; Nestler et al., 2002b) . Such models have revealed a variety of stress-induced effects in the brain, such as impaired neurotrophin signaling (Rasmusson et al., 2002; Gronli et al., 2006) , atrophy of hippocampal CA3 pyramidal neurons (Magarinos et al., 1996) , reduced synaptic plasticity (Joels et al., 2009 ) and suppressed neurogenesis in the dentate gyrus (Fuchs and Flugge, 1998; Gould and Tanapat, 1999) . Together, these changes have been suggested to play a role in the development of neuronal dysfunctions and ultimately increase one's vulnerability to psychopathology (Krishnan and Nestler, 2008) . One of the brain areas particularly sensitive to stress is the hippocampus, a region involved in cognition, mood and neuroendocrine stress reactivity. There is a large body of data supporting the notion that the hippocampus plays a role in depression and the action of antidepressant drugs (Alfonso et al., 2005) . The hippocampus is also one of the few regions of the brain where new neurons are generated in adulthood (Abrous et al., 2005; Ming and Song, 2005) . Hippocampal neurogenesis has been established in several different species (Gould, 2007) , including primates (Gould et al., 1999c) and humans (Eriksson et al., 1998) . During the last decade, numerous studies focused on the hypothesis that changes in hippocampal neurogenesis and plasticity in general contribute to the etiology of depression as well as to the action of antidepressant drugs (Jacobs et al., 2000; Duman, 2004b; Fuchs et al., 2004; Drew and Hen, 2007; Lucassen et al., 2010) .
Preclinical studies suggest that antidepressants may exert their therapeutic effects by enhancing neurotrophin signaling and promoting the formation of new hippocampal neurons as well as new synaptic connections in the brain (Castren, 2004a; Duman, 2004a) . Such effects have been described for many antidepressant treatments, including serotonin-and norepinephrine-enhancing drugs (Malberg et al., 2000; Manev et al., 2001) , electroconvulsive seizures (Madsen et al., 2000) , and lithium (Chen et al., 2000) . In agreement with this, also the novel antidepressant agomelatine promotes hippocampal neurogenesis under basal conditions (Banasr et al., 2006; Soumier et al., 2009) .
In the present study we used a chronic footshock stress model in order to test the effects of agomelatine under conditions of severe and prolonged stress. This footshock model was previously shown to promote HPA-axis hyperactivity, induce robust changes in gene expression in stress-related brain areas, target intracellular signaling cascades involved in neuronal plasticity and affect hippocampal neurogenesis (Trentani et al., 2002; Kuipers et al., 2003; Trentani et al., 2003; Westenbroek et al., 2004; Kuipers et al., 2006; Dagyte et al., 2009 ). Here we investigated whether treatment with agomelatine is effective in the brain, exposed to chronic stress. First, we examined whether daily treatment with agomelatine for 21 consecutive days changed HPA-axis reactivity, induced by footshock stress. Then, in 67 CHAPTER 3 order to gain further insight in the processes targeted by stress and antidepressant therapy, we investigated whether agomelatine induced changes in neuronal activity as well as hippocampal neurogenesis.
EXPERIMENTAL PROCEDURES

Animals and housing
The experiments were performed using adult (10-12 weeks of age) male Wistar rats 
Experimental protocol
Four groups of rats were used for the present experiments: two groups of home cage control rats (CTR), which were treated either with vehicle (CTR Veh) or agomelatine (CTR Ago), and two groups of chronically stressed rats (STR), which were also treated either with vehicle (STR Veh) or agomelatine (STR Ago). Each group consisted of 8 animals. The home cage control rats were sacrificed concomitantly with the stressed rats which were euthanized 24 h after the last footshock exposure.
Stress procedure
During a 2-week acclimatization period before the start of the experiments, all rats were weighed and handled daily. Footshock stress was applied in a footshock box with a grid floor connected to a shock generator and scrambler (Trentani et al., 2003; Dagyte et al., 2009) . Stress group rats were subjected to a daily session of footshock stress for 21 consecutive days. During the session in the footshock box rats received 5 uncontrollable and inescapable footshocks (0.8 mA in intensity and 8 s in duration). All footshock sessions took place during the light phase. In order to increase unpredictability and minimize habituation, both timing and duration of footshock sessions as well as intervals between shocks within a session varied 68 randomly (session starting time: between 08:00 and 13:00 h; session duration: 15-80 min; shock interval: 1-15 min), with the exception of the sessions on day 1, 11 and 21. On these days, all animals received footshock sessions of 20 min with shock intervals of 5 min to allow standardized neuroendocrine measurements. Control rats stayed undisturbed in their home cages throughout the experiment.
Drug treatment
1% hydroxyethylcellulose (HEC) was used as a vehicle for agomelatine delivery.
Agomelatine solution was prepared every day by dissolving agomelatine powder in 1% HEC at a concentration of 40 mg/ml. The choice of the agomelatine dose was made on the basis of its activity at this concentration in animal models of depression and anxiety (Papp et al., 2003; Millan et al., 2005) , and on neurogenesis (Banasr et al., 2006; Soumier et al., 2009 ). Rats were injected intraperitoneally either with agomelatine (40 mg/kg) or vehicle daily at 16:00 (2 h prior to the dark phase) for 21 days.
Neuroendocrine measurements
In order to determine activation of the HPA-axis by footshock stress and changes herein during the experiment, blood samples were collected by tail bleeding and analyzed for adrenocorticotropic hormone (ACTH) and corticosterone (Meerlo et al., 2002) . Blood was collected on day 1, 11 and 21 of the chronic stress period. Each time, three samples were taken from all stress group rats: baseline (before the footshock procedure), stress (at the end of the 20-min footshock session), and recovery (30 min after the session in the footshock box). Home-cage control rats were sampled once at the beginning of the light phase, simultaneously with the stress group rats. Blood samples were collected in microcentrifuge tubes containing EDTA as the anticoagulant, and kept on ice. Then, blood was centrifuged at 2600 g for 15 min and the supernatant stored at −80 °C until radioimmunoassay measurements of ACTH and corticosterone were performed.
BrdU labeling
In order to study survival of newly-born cells in the hippocampus during the 
Brain collection & immunohistochemistry
At the end of the experiment, 24 h after the last stress session and 18 h after the last agomelatine injection, rats were anesthetized with sodium pentobarbital and transcardially perfused with heparinized saline followed by 4% paraformaldehyde solution in 0.1 M phosphate buffer. Brains were extracted and post-fixed in the same solution overnight at 4°C and subsequently cryoprotected by immersion in a 30% buffered sucrose solution for up to 48 h. Coronal serial sections of 30 μm were cut using a cryostat and stored in 0.01 M phosphate-buffered saline with 0.1% sodium azide at 4°C until immunohistochemistry was performed.
In order to assess effects of agomelatine and chronic footshock stress on different aspects of hippocampal neurogenesis, immunohistochemistry for Ki-67, doublecortin (DCX), and BrdU was performed. Ki-67 is a nuclear protein which is expressed during all phases of the cell cycle, except G0 (Scholzen and Gerdes, 2000), which would therefore give an indication of cell proliferation on the last day of the experiment. DCX protein is expressed in newly-born cells from 1 day to about 4 weeks of age, and might therefore reveal sustained changes in the neurogenesis process and its modulation (Brown et al., 2003; Rao and Shetty, 2004) . Finally, since a pool of newborn cells was labeled with an injection of BrdU 4 days prior to the start of the experiment, BrdU immunostaining would indicate changes in survival of new cells in the course of the experiment.
Effects of agomelatine and chronic footshock stress on neuronal activity were assessed by immunohistochemistry for the immediate early gene c-Fos (Kovacs, 1998; Hoffman and Lyo, 2002) .
The immunostainings were performed on free-floating sections under continuous mild agitation. BrdU immunohistochemistry required extra steps for DNA denaturation. For this purpose, sections were exposed to 2x saline sodium citrate (2xSSC) containing 50% formamide for 30 min at 65°C, followed by a rinse with 2xSSC, incubation with 2 M HCl for 30 min at 37°C and a washing step with 0.1 M borate buffer. Brain sections for all four immunostainings were preincubated in 3% normal serum and 0.1% TritonX-100, and then incubated with one of the following antibodies for 60 h at 4°C: primary mouse-anti-Ki-67 (1:200; Monosan, Uden, The Netherlands), goat-anti-DCX (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rat-anti-BrdU (1:800; Serotec, Oxford, UK) or rabbit-anti-c-Fos (1:10000; Calbiochem, Darmstadt, Germany). Subsequently, sections were rinsed in 0.01 M Tris-buffered saline and incubated for 2 h at room temperature with secondary biotinylated goat-anti-mouse, rabbit-anti-goat, donkey-anti-rat or goat-anti-rabbit antibody depending on the primary antibody host (1:500 for all secondary antibodies, Jackson ImmunoResearch Suffolk, UK). Then, avidin-biotin complex (1:500, Vector ABC kit, Vector Laboratories, Burlingame, CA, USA) was added for 2 h, after which the staining was visualized with 1 mg/ml diaminobenzidine and 0.003% H2O2.
Thereafter, sections were rinsed, mounted on slides, dehydrated and coverslipped for microscopic analysis. Due to technical problems, brain sections of two animals were excluded from DCX and c-Fos immunostainings.
Quantification
All analyses were performed by an observer blind to the group assignment. and BrdU positive cells were counted in the subgranular zone (SGZ) and granular cell layer (GCL) of the dentate gyrus in every twelfth section of the hippocampus under 500× magnification. Immunopositive cells that were located one cell diameter away from SGZ were also included in the analysis. The number of immunopositive cells in each section was expressed relative to the length of the dentate gyrus in order to correct for variation in size of the hippocampus along the rostro-caudal axis of the brain. The length of the dentate gyrus was measured by delineating the entire SGZ in each hippocampus. DCX immunoreactivity (ir) in cell bodies and dendrites of the newly generated cells was measured by a previously described method (Dagyte et al., 2009) . Briefly, optical density (OD) of DCX expression was measured in the DG and corrected for non-specific background labeling, which was measured in the corpus callosum. In total, 7-8 sections per animal (Bregma -2.56 to -6.30, according to the rat brain atlas, Paxinos & Watson, 2 nd edition) were analyzed by delineating a similarly sized area covering the entire width of SGZ and GCL in each hippocampus.
Images were taken using a Leica charged-coupled device digital camera mounted on a microscope (DMIRB, Leica, Cambridge, UK) at 100× magnification. The OD was expressed in arbitrary units corresponding to grey levels using a Quantimet 550 image analysis system (Leica, Cambridge, UK). In all three stainings, dorsal and ventral hippocampi were analyzed separately. When similar changes in the dorsal and ventral parts of hippocampus were detected, these data were pooled and effects in the entire hippocampus were presented. 
RESULTS
Food intake and body weight
Food intake and body weight were measured from day -4 to day 22 of the experiment. All rats ate and grew at similar rates during the acclimatization period.
Chronic footshock stress reduced food intake (repeated measures ANOVA, time x stress interaction: F(20,560)=22.02, p<0.001), whereas agomelatine had no significant effect ( figure 3.1A) . In contrast, body weight gain was strongly reduced by both 
ACTH and corticosterone levels
Changes in plasma ACTH and corticosterone concentrations in response to footshock exposure and agomelatine treatment are shown in figure 3.2. Baseline ACTH and corticosterone levels did not differ among the groups. As expected, footshock stress induced a robust HPA-axis activation (repeated measures ANOVA, stress effect:
ACTH: F(8,112)=91.06, p<0.001; CORT: F(8,112)=111.31, p<0.001; stress vs. baseline: p<0.001). The peak ACTH levels in vehicle treated animals on day 21 did not differ from the peak ACTH levels on day 1 and day 11 of the experiment. In agomelatine treated animals, the peak ACTH levels on day 21 were significantly lower as 73 CHAPTER 3
Figure 3.2 Plasma concentrations of ACTH and CORT in response to footshock stress on day 1, 11 and 21 of the experiment. Since on day 1 blood was sampled before the drug treatment started, the data of rats assigned to either vehicle or agomelatine groups were pooled. Exposure to the footshock significantly elevated both ACTH and corticosterone levels as compared to baseline values (p<0.001). Chronic agomelatine treatment did not significantly influence either basal or stress-induced HPA-axis activity.
compared to the peak ACTH levels on day 1, but not day 11 of the experiment (repeated measures ANOVA, stress x drug interaction: F(8,112)=2.39, p=0.02; day1-stress vs. day21-stress: p=0.008; day1-stress vs. day11-stress and day11-stress vs. day21-stress: p>0.05). However, there were no significant differences between the peak ACTH levels of vehicle and agomelatine treated rats on any of the days tested (p>0.05). There were no differences in corticosterone response between vehicle and agomelatine treated rats at any time point. areas of hippocampus, they were not statistically significant (drug effect and stress x drug interaction: p>0.05). cells / mm). Therefore, these data were pooled in order to present effects in the entire hippocampus (figure 3.6A). Two-way ANOVA revealed a significant drug effect and a significant stress x drug interaction in proliferating cell numbers (F(1,28)=10.33, p=0.003 and F(1,28)=5.08, p=0.03, respectively). Post-hoc Fisher LSD test showed that agomelatine significantly increased the number of Ki-67-positive cells in stressed animals (STR Veh vs. STR Ago, p<0.001), whereas it had no effect in control animals (CTR Veh vs. CTR Ago, p>0.05).
Hippocampal neuronal activity
Hippocampal neurogenesis
Hippocampal cell survival was assessed by BrdU immunohistochemistry ( figure   3 .5B). Whereas no significant effects were observed in the dorsal dentate gyrus (CTR 
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CHAPTER 3 stressed animals (STR Veh vs. STR Ago, p=0.04), whereas it had no effect in control animals (CTR Veh vs. CTR Ago, p>0.05).
Effects of stress and agomelatine on newly-born hippocampal cell maturation were assessed by DCX labeling ( figure 3.5C Therefore, these data were pooled in order to present effects in the entire hippocampus ( figure 3.6C) . Two-way ANOVA revealed a significant stress x drug interaction (F(1,26)=29.39, p<0.001). Post-hoc Fisher LSD test showed that both chronic stress and agomelatine reduced DCX expression in the dentate gyrus (CTR Veh vs. STR Veh: p<0.001; CTR Veh vs. CTR Ago, p<0.001). In stressed animals, agomelatine reversed the decrease in DCX expression in the dentate gyrus (STR Veh vs. STR Ago: p=0.001).
DISCUSSION
Agomelatine administered to chronically stressed rats induced changes in the brain, extending from hippocampal neuronal activity to adult neurogenesis. Whereas chronic exposure to daily footshock stress reduced c-Fos expression in the dentate gyrus, agomelatine treatment reversed this effect and normalized neuronal activity to basal levels. Chronic agomelatine also enhanced hippocampal cell proliferation in rats concurrently exposed to chronic stress and promoted survival of the newly-born cells selectively in the ventral hippocampus. Finally, agomelatine treatment reversed the stress-induced decrease in DCX expression. Taken together, these data show that agomelatine is beneficial in the stress-compromised brain. Our findings suggest that antidepressant action of agomelatine may depend on its ability to reverse stress-affected neuronal activity and promote hippocampal neurogenesis.
Chronic footshock stress was associated with a significant hypophagic effect, confirming the previous reports on reduced body weight gain in stressed male rats (Trentani et al., 2003; Dagyte et al., 2009) . The 3-week treatment with agomelatine also led to a reduction in growth, although a similar change in body weight in rats of the same strain was not observed in an earlier study after 7-week agomelatine treatment (Papp et al., 2003) . Reductions in growth were also reported after SSRI administration in rats, in which case it appeared to be a result of decreased food intake (Wurtman and Wurtman, 1977; Luo and Li, 1991) . However, agomelatine administration in our study did not affect food intake. Although agomelatine is not 78 only a potent melatonin receptor agonist but also acts as a 5-HT2C antagonist, the decrease in body weight is most likely a melatonin receptor-mediated effect. In rodents, melatonin was reported to decrease body weight without changes in food intake, whereas different 5-HT2C antagonists were either shown to increase it or to have no effect (Wolden-Hanson et al., 2000; Vickers and Dourish, 2004) . In contrast to the body weight decrease in rats, agomelatine does not appear to affect body weight in monkeys and humans (Rouillon, 2006; Kasper and Hamon, 2009 ).
Footshock stress has been shown to cause a severe activation of the HPA-axis (Dagyte et al., 2009) . Pronounced increases in both ACTH and corticosterone were observed here in response to this form of stress. No habituation in the peak responses was noted, even after three weeks of daily exposure to footshock.
Agomelatine treatment did not dramatically influence either basal or stress-induced HPA-axis activity. Our data are in line with previous reports where chronic agomelatine had no effect on the HPA-axis parameters after immobilization stress in mice or after predator stress in rats (Barden et al., 2005; Conboy et al., 2009 ). On the other hand, this antidepressant has been shown to normalize stress-induced increase in cortisol in the tree shrew model of chronic stress (Fuchs et al., 2006) . Differences in the type of stressors and animal species used might be responsible for this inconsistency.
Our c-Fos data suggest that agomelatine acts by normalizing reduced neuronal activity in hippocampus, a brain area sensitive to stress and often implicated in mood disorders. It is interesting to note that whereas several stress-related brain areas display increased c-Fos expression in response to repeated footshock stress, the dentate gyrus of the hippocampus is associated with reduced activation of this immediate early gene (Trentani et al., 2003; Huang et al., 2004) . Here, we observed that such chronic stress-induced suppression of c-Fos expression in the dentate gyrus is prevented by agomelatine treatment. Similar changes were noted in CA3 and CA1 regions of the hippocampus, although these did not reach statistical significance. The CA regions showed fewer c-Fos-positive cells than the dentate gyrus, which might have hampered the detection of significant differences between the groups. The c-Fos induction reflects the functional activity of the neurons (Kovacs, 1998) . Therefore, alterations in neuronal activity may indirectly indicate changes in hippocampal information processing. Although the functional interpretation of c-Fos changes deserves caution, it is tempting to speculate that by normalizing stress-affected neuronal activity in the dentate gyrus, agomelatine may rescue the functional integrity of hippocampal circuitry.
Prolonged footshock stress did not significantly affect hippocampal cell proliferation or survival in our experiment. The lack of significant stress-mediated 79 CHAPTER 3 effects on these processes may depend on the timing of sacrifice of the animals as compared to the last stress session or BrdU labeling. Animals were in fact euthanized 24 hours after the final footshock session. This delay may be sufficient to weaken the inhibitory influences of stress on cell proliferation. A recent study revealed that chronic footshock stress leads to short-lasting suppression of cell proliferation which can easily go unnoticed if animals are sacrificed 24 hours after stress (Dagyte et al., 2009) . Interestingly, agomelatine promoted hippocampal cell proliferation and, to a lesser extent, cell survival, in rats subjected to chronic footshock stress. Whereas agomelatine-induced increase in cell proliferation was observed in the entire hippocampus, cell survival was selectively enhanced in the ventral hippocampus, a region particularly involved in response to stress and anxiety (Bannerman et al., 2004) . Current literature regarding agomelatine-induced effects on hippocampal neurogenesis is scarce. Yet, it has been shown that 3-week agomelatine treatment increased cell proliferation in the ventral dentate gyrus of non-stressed Wistar rats, whereas extending the treatment for additional 3 weeks also promoted cell survival in the entire dentate gyrus (Banasr et al., 2006) . Agomelatine-mediated effect on hippocampal cell proliferation was recently corroborated by another study, which, in addition, reported that agomelatine administration for 15 or 21 days increased cell survival (Soumier et al., 2009 ).
However, unpublished data suggest that 6-week agomelatine treatment had no effect on cell survival in non-stressed Sprague-Dawley rats (Maccari et al., 2005) . Notably, our data indicate that chronic agomelatine did not influence hippocampal cell proliferation or survival in non-stressed rats. Discrepant effects among studies may be due to subtle changes in the experimental protocols, such as timing of BrdU injection in relation to agomelatine administration and animal sacrifice. Grouphousing conditions (three rats per cage) in the experiments performed by the team of Daszuta might also account for different outcomes in the rates of cell proliferation and survival (Banasr et al., 2006; Soumier et al., 2009) In summary, this study elucidated several neurobiological processes targeted by agomelatine treatment in chronically stressed rats. First, agomelatine normalized stress-affected neuronal activity in the dentate gyrus of the hippocampus. Second, agomelatine stimulated hippocampal cell proliferation and survival under conditions of chronic stress. Third, treatment with agomelatine reversed the stress-induced decrease in DCX expression in the dentate gyrus. Taken together, these data indicate that agomelatine is beneficial in the stressed brain, where it preserves the functional activity of hippocampal neuronal circuitry and promotes hippocampal neurogenesis.
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